Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Meropenem/vaborbactam (Vaborem®) is recommended as an option for restricted use within NHS Wales. Meropenem/vaborbactam (Vaborem®) is licensed for the treatment of complicated urinary tract infection (cUTI) including acute pyelonephritis (AP), complicated intra-abdominal infection (cIAI), hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP) in adults; and for the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Meropenem/vaborbactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options. Meropenem/vaborbactam (Vaborem®) is restricted for use in the sub-population of adult patients with confirmed carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) associated infections. Meropenem/vaborbactam (Vaborem®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | meropenem/vaborbactam (Vaborem®) | ||
| Formulation | 1 g/1 g solution for infusion | ||
| Reference number | 2760 | ||
| Indication | Treatment of complicated urinary tract infection including pyelonephritis, complicated intra-abdominal infection, hospital-acquired pneumonia including ventilator associated pneumonia in adults and for the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Meropenem / vaborbactam is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options |
||
| Company | Menarini Farmaceutica Internazionale srl | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 1120 | ||
| NMG meeting date | 09/09/2020 | ||
| AWMSG meeting date | 13/10/2020 | ||
| Date of issue | 22/10/2020 | ||